PCVX: 31-Valent vaccine nears phase III, targeting major market growth and expanded global demand
阅读少于1分钟
A 31-Valent Pneumococcal Conjugate Vaccine is advancing to phase III in adults, with strong phase II data showing superior coverage and immune response. The market is expected to grow rapidly, especially in adults, and manufacturing capacity is being expanded to meet global demand.
Based on Vaxcyte, Inc. [PCVX] Jefferies London Healthcare Conference 2025 Audio Transcript — Nov. 19 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr